Blood collection and overview (routine) measurements
LASA file name(s):
LASAB850 / LASAC850 / LAS2B850 / LASAG850 / LAS3B850: Response blood sampling / DNA
LASAB851 / LASAC851 / LAS2B851 / LASAG851 / LAS3B851: Date blood sampling (including time point when available)
LASAB860 / LASAC860 / LAS2B860 / LASAG860 / LAS3B860: Routine measurements, for additional details see: Routine measurements
Contact: Natasja van Schoor
Blood collection first cohort (B-, C- and G-cycle)
At the LASA B-cycle (1992/93), blood was collected in the regions Amsterdam and Zwolle; no blood was collected in Oss. Non-fasting blood samples were taken during the medical interview while the subject was sitting. The blood that was obtained during this cycle was centrifuged and stored at -80° until determination. Several routine determinations were performed immediately, this concerns blood of the region Zwolle and part of the region Amsterdam (Table 5). In the region Zwolle this was done in the ISALA clinic; in Amsterdam this was done in the PCA Valeriuskliniek. See Table 1 for the response rates.
At the LASA C-cycle (1995/96), blood samples were obtained from respondents who participated in the medical interview of LASA (1995/96), were born in 1930 and before (aged 65 years and older as of 1 January, 1996) and were living in Amsterdam, Zwolle and Oss and surroundings. Of the 1,720 respondents who were eligible for the medical interview, 1,509 took part in the medical interview. After this interview at home, participants were invited to the VUmc (respondents living in Amsterdam and vicinity) or a health care center near their homes (respondents living in Zwolle or Oss and vicinity), where blood samples were obtained. For respondents who were not able to come to the VUmc, blood samples were drawn at home (n=76). Blood samples were available for 1,331 respondents. At the visit in the hospital or health care center, fasting urine and blood samples were obtained, centrifuged and stored at -80° or analyzed immediately. In the region Zwolle the immediate assays were done in the ISALA clinic; in Amsterdam this was done in the VUmc; in Oss, this was done in the Bernhoven Hospital. Respondents were allowed to take tea and toast, but no dairy products. In Amsterdam, morning blood samples were collected (between 8.30 and 9.30 a.m.); in Zwolle, blood samples were collected during the daytime; in Oss, morning blood samples were collected (between 8.00 and 10.00 a.m.).. See Table 1 for the response rates.
At the LASA G-cycle (2008/09), fasting blood samples were drawn in Amsterdam, Zwolle and Oss and surroundings. Subjects were not allowed to take any food or drinks from midnight. Of 58 respondents, blood samples were drawn at home. The other participants were sampled on location. The samples were centrifuged and stored at -80° or analyzed immediately. See Table 1 for the response rates.
In general:
Blood sampling took place within 4 to 6 weeks after the medical interview of LASA, except for the B-cycle where blood sampling took place at home during the medical interview. Routine determinations were performed immediately after blood sampling in the lab where the blood was collected (in case of using health care centers near the home of a respondent, or home visit, the blood was transported to the central laboratory of each region). Samples were centrifuged within 4 hours. It should be noted that different labs were used in the different regions. Furthermore, when comparing routine measurements performed in fresh blood over time, it should be noted that at the B-cycle a different laboratory was used in Amsterdam (PCA Valeriuskliniek) than at later cycles (VUmc). All blood samples are stored at -80°. However, in case of a new determination in blood, the blood is temporarily stored at the laboratory at -20°.
Laboratory determination
Albumin, creatinine and total cholesterol were determined as routine measurements in fresh blood at LASA B and C; fasting glucose was additionally assessed at LASA G. For an overview of the most important biomaterial measurements, see Table 4. For a detailed overview of routine measurements, see Table 5.
Table 1. Response first cohort
| Cycle | Total medical interview |
Number of blood samples |
Response (%) |
|---|---|---|---|
| B1 | 2675 (2671)2 | 17843 | 66.7 |
| C | 1509 | 1331 | 88.2 |
| G4 | 761 | 400 | 52.6 |
1 No blood was collected in Oss in the B-cycle.
2 In 4 persons, data of the medical interview were lost.
3 In part of Amsterdam blood was collected but routine measurements were not determined immediately (n=502) in the B-cycle.
4 At the G-cycle, a combined blood collection was performed in the first and second cohort. Reported numbers include only the first cohort.
Blood collection second cohort (2B- and G-cycle)
At the LASA 2B cycle (2002/03), blood samples were collected in Amsterdam, Zwolle and Oss and surroundings. Respondents were allowed to take tea and toast, but no dairy products. In Amsterdam, morning blood samples were collected (between 8.30 and 9.30 a.m.); in Zwolle, blood samples were collected during daytime; in Oss, morning blood samples were collected (between 8.00 and 10.00 a.m.). Of 15 participants, blood samples were drawn at home. The other participants were sampled on location. The samples were centrifuged and stored at -80° or analyzed immediately. See Table 2 for the response rates.
At the LASA G-cycle (2008/09), fasting blood samples were drawn in Amsterdam, Zwolle Oss and surroundings. Subjects were not allowed to take any food or drinks from midnight. Of 11 participants, blood samples were drawn at home. The other participants were sampled on location. The samples were centrifuged and stored at -80° or analyzed immediately. See Table 2 for the response rates.
Laboratory determination
Albumin, creatinine and total cholesterol were determined as routine measurements in fresh blood at LASA 2B; fasting glucose was additionally assessed at LASA G. For an overview of the most important biomaterial measurements, see Table 4. For a detailed overview of routine measurements, see Table 5.
Table 2. Response second cohort
| Cycle | Total medical interview | Number of blood samples |
Response (%) |
|---|---|---|---|
| 2B | 919 | 748 | 81.4 |
| G1 | 733 | 535 | 73.1 |
1 At the G-cycle, a combined blood collection was performed in the first and second cohort. Reported numbers include only the second cohort.
Blood collection third cohort (3B cycle)
At the 3B-cycle (2012/13), fasting blood samples were drawn. Subjects were not allowed to take any food or drinks from midnight. The samples were centrifuged and stored at -80° or analyzed immediately. See Table 3, for the response rates.
Laboratory determination
Fasting glucose was assessed as a routine measurement in fresh blood (Table 4).
Table 3. Response third cohort
| Cycle | Total medical interview | Number of blood samples |
Response (%) |
|---|---|---|---|
| 3B | 889 | TBD | TBD |
TBD=To be determined
Table 4. Most important biomaterial measurements and realized sample size (see also the European Journal of Epidemiology 2016)
| Routine measurements in fresh blood | B d | C | 2B | G | 3B |
| Albumin | 1507 | 1326 | 747 | 924 | – |
| Creatinine | 1507 | 1327 | 747 | 925 | – |
| Total cholesterol | 1507 | 1309 | 744 | 923 | – |
| Fasting glucose | – | – | – | 918 | 640 |
| Measurements in frozen blood a | B d | C | 2B | G | 3B b |
| Total cholesterol | – | 1296 | – | – | – |
| Creatinine | – | – | – | – | 632 |
| High-density lipoprotein (HDL) cholesterol | – | 1295 | – | – | – |
| Low-density lipoprotein (LDL) cholesterol | – | 1287 | – | – | – |
| Triglycerides | – | 1296 | – | – | – |
| Fructosamine | – | 1298 | – | – | – |
| Adipokines (adiponectin, leptin, ghrelin) | – | – | – | 897 | – |
| Total plasma cortisol | – | 1279 | – | – | – |
| Cortisol binding globulin (CBG) | – | 1277 | – | – | – |
| Homocysteine | – | 1301 | – | – | – |
| Vitamin B12 | – | 1276 | – | – | – |
| Methylmalonic acid (MMA) | – | 582 | – | – | – |
| Sex hormone-binding globulin (SHBG) | – | 1320 | – | – | – |
| Insulin-like growth factor 1 (IGF-1) | – | 1319 | – | – | – |
| Osteocalcin (OC) | – | 1319 | – | – | – |
| Pro-inflammatory cytokine Interleukin-6 (IL-6) | 1745 | 1287 | – | – | 638 |
| Acute-phase proteins C-reactive protein (CRP) | 1744 | 1287 | – | – | 631 |
| Alpha-1-antichymotrypsin (ACT) | 1743 | 1284 | – | – | – |
| Serum 25-hydroxyvitamin D (25-OHD) | – | 1320 | 739 | 916 | 639 |
| Parathyroid hormone (PTH) | – | 1320 | 739 | 915 | – |
| Follicle stimulating hormone (FSH) | – | 1301 | – | – | – |
| Luteinizing hormone (LH) | – | 1301 | – | – | – |
| Testosterone | – | 630 | – | – | – |
| Estradiol | – | 1301 | – | – | – |
| Thyroid stimulating hormone (TSH) c | – | 1270 | – | – | – |
| Vitamin K (dp-ucMGP + dp-cMGP) | – | – | 696 | – | – |
| Other measurements | C | E | Ancillary study (2010-11) |
||
| Urine deoxypyridinolin (DPD) | 1307 | – | – | ||
| Urine creatinine | 1311 | – | – | ||
| Salivary cortisol | – | 1199 | – | ||
| Hair cortisol | – | – | 333 | ||
| DNA | First cohort | Second cohort | Third cohort | ||
| Exome chip analysis | 1193 | – | NYAa | ||
| Apolipoprotein E (ApoE) phenotyping | 2233 | – | |||
| Apolipoprotein E (ApoE) genotyping | – | 753 | |||
| Collagen type I α1 Sp1 polymorphism | 966 | – | |||
| Single nucleotide polymorphisms Vitamin D Receptor | 935 | – | |||
| Single nucleotide polymorphisms Glucocorticoid Receptor | 935 | – |
a NYA=Not yet available. New blood determinations may become available in the future from frozen blood.
b Partly available: Blood has been collected (n = 640), but not all assessments have been performed yet.
c In case of abnormalities in TSH level, Tri-jodothyronin (T3) and/or Thyroxin (T4) were measured.
d Measurements in cycle B were only done in Amsterdam and Zwolle, in other cycles in all regions.
Table 5. Detailed overview of routine measurements in fresh blood in first and second cohort a
| First cohort B-cycle (n=2675) b |
First cohort C-cycle (n=1509) c |
First cohort G-cycle (n=761) d |
Second cohort 2B-cycle (n=919) e |
Second cohort G-cycle (n=733) f |
|
| N= valid data | N= valid data | N= valid data | N= valid data | N= valid data | |
| Haemoglobine mMol/L | 1509 | 400 | – | 282 | – |
| Haematocriet LL | 1508 | 400 | – | 280 | – |
| Erythrocyten x(10 power 12)/L |
1508 | 400 | – | 280 | – |
| Leucocyten x(10 power 9)/L |
1494 | 398 | – | 280 | – |
| Multi cellulair haemoglobine a Mol |
736 | – | – | – | – |
| Multi cellulair volume FL | 736 | – | – | – | – |
| Multi cellulair haemoglobine concentration mMol/L |
736 | – | – | – | – |
| Creatinine uMol/L | 1507 | 1327 | 395 | 747 | 530 |
| Albumine g/L | 1507 | 1326 | 395 | 747 | 529 |
| Total cholesterol mMol/L | 1507 | 1309 | 395 | 744 | 528 |
| Cholesterol/HDL ratio | 1502 | 404 | – | 283 | – |
| Ferro uMol/L | 773 | 404 | – | 283 | – |
| Vitamine B12 pMol/L | 767 | 404 | – | 283 | – |
| Foliumacid nMol/L | 772 | 400 | – | 283 | – |
| TSH mU/L | 769 | 398 | – | 283 | – |
| CRP mG/L | 223 | 404 | – | 283 | – |
| Calcium mMol/L | 773 | 404 | – | 283 | – |
| Ureum mMol/L | 773 | 404 | – | 283 | – |
| Total Protein G/L | 773 | 404 | – | 283 | – |
| OT (ASAT) U/L | 773 | 404 | – | 283 | – |
| PT (ASAT) U/L | 773 | 404 | – | 283 | – |
| Gamma GT U/L | 773 | 404 | – | 283 | – |
| Glucose mMol/L | 773 | 404 | 391 | 283 | 527 |
| Triglyceriden mMol/L | 773 | 404 | – | 283 | – |
| HDL mMol/L | 770 | 404 | – | 283 | – |
| Free T4 pMol/L | 773 | 404 | – | 283 | – |
| LDL mmol/L | 768 | 404 | – | 283 | – |
| BSE mm/U | 1505 | 398 | – | 276 | – |
a See Tables 1 and 2 for the response rate for each cohort and measurement wave.
b First cohort, B-cycle: measurements in red were performed in Amsterdam and Zwolle (not in Oss), measurements in blue only in Zwolle.
c First cohort, C-cycle: measurements in bold were done in all regions (Amsterdam, Zwolle and Oss), measurements in blue only in Zwolle.
d First cohort, G-cycle: measurements in bold were done in all regions.
e Second cohort, 2B-cycle: measurements in bold were done in all regions, measurements in blue only in Zwolle.
f Second cohort, G-cycle: measurements in bold were done in all regions.
Date of last update: April 22, 2020
